Business
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 15 / 2025","length":36,"tagName":"p"},{"type":"text","content":"Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide","length":128,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modifications","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Unique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":523,"olType":false},{"type":"text","content":"Copenhagen, Denmark, June 18, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces positive topline clinical results from Part 2 of a Phase 1b multiple ascending dose (MAD) trial, investigating safety, tolerability, and clinical effects of 28 weeks of treatment with dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist1.","length":457,"tagName":"p"},{"type":"text","content":"“We are very encouraged by the impressive weight loss with dapiglutide after 28 weeks that appears on par with the most efficacious once-weekly GLP-1 receptor agonist-based therapy on the market today, despite the almost entirely male and relatively le...